Knilonat 150mg Capsule

Knilonat 150mg Capsule is an anticancer medicine with Nilotinib (150mg) as an active ingredient. It is prescribed to treat chronic myeloid leukaemia a type of blood cancer. It works by blocking the action of specific proteins to slow down the growth of cancer cells and progression of disease. It can be used alone or in combination with other medicines. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

• Blood cancer (Chronic myeloid leukaemia)

Every medicine has some side effects that typically manage on their own as your body gets used to the medicine, but some people may experience severe side effects rarely. In that case, the patient should contact the doctor immediately.
Some common side effects of Knilonat 150mg Capsule  include:

• Fatigue
• Headache
• Nausea
• Muscle pain
• Abdominal pain
• Rash
• Itching
• Hair loss

Contact your healthcare provider if you face any unusual or persistent side effects.

• The dosage and duration of the Knilonat 150mg Capsule are decided by the doctor based on the severity of the cancer and other health factors. Take this tablet on an empty stomach for better results. Before starting this medicine, please inform your doctor about your medical history.
• If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.
  
  

Knilonat 150mg Capsule contain active ingredient Nilotinib. It is a targeted therapy based anticancer drug that works by blocking the action of proteins (kinases) which are responsible for the growth and division of cells. Results in slows the growth of cancer cells and eventually kills them.

• DeRemer, D. L., Ustun, C., & Natarajan, K. (2008). Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clinical therapeutics, 30(11), 1956-1975. https://pubmed.ncbi.nlm.nih.gov/19108785/
• Rosti, G., Palandri, F., Castagnetti, F., Breccia, M., Levato, L., Gugliotta, G., ... & GIMEMA CML Working Party. (2009). Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood, The Journal of the American Society of Hematology, 114(24), 4933-4938. https://pubmed.ncbi.nlm.nih.gov/19822896/
• Saglio, G., Kim, D. W., Issaragrisil, S., Le Coutre, P., Etienne, G., Lobo, C., ... & Kantarjian, H. M. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. New England Journal of Medicine, 362(24), 2251-2259. https://pubmed.ncbi.nlm.nih.gov/20525993/
• Blay, J. Y., & von Mehren, M. (2011, April). Nilotinib: a novel, selective tyrosine kinase inhibitor. In Seminars in oncology (Vol. 38, pp. S3-S9). WB Saunders. https://pubmed.ncbi.nlm.nih.gov/21419934/
• Quintás-Cardama, A., Kantarjian, H., & Cortes, J. (2012). Nilotinib-associated vascular events. Clinical Lymphoma Myeloma and Leukemia, 12(5), 337-340. https://pubmed.ncbi.nlm.nih.gov/22633167/